Do you need more information
The VIDAS® Chikungunya panel includes 2 immunoassays recommended by international guidelines to detect anti-chikungunya IgM and IgG antibodies at different phases of the disease.
Do you need more information
Transmitted to humans through the bites of infected mosquitoes, chikungunya virus (CHIKV) was first identified in Tanzania in 1952. Over the last two decades it has spread across the world to more than 100 countries, causing regular outbreaks in Asia and Africa, massive outbreaks in the Americas, and more sporadic and clustered cases in Europe.
As symptoms of chikungunya overlap with those of other mosquito-borne diseases, such as dengue and malaria, differential diagnosis in endemic areas is essential for optimized patient management. The VIDAS® CHIKUNGUNYA panel offers a complete solution for rapid and reliable confirmation of chikungunya infection.
Recommended diagnostic methods(1)
3 specific chikungunya biomarkers are expressed after infection:
2 complementary tests
The VIDAS® CHIKUNGUNYA panel offers 2 complementary tests for accurate detection of the disease from the acute to the chronic phase:
VIDAS® Anti-CHIKUNGUNYA IgM | VIDAS® Anti- CHIKUNGUNYA IgG |
Immunocapture allows excellent performance(2) | No cross reactivity with dengue, Zika, yellow fever and SARS-COV-2(2) |
High sensitivity on follow-up of CHIKV positive patients: 100% (11-21 days) (2) |
Developed with the contribution of the United States National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC)
The VIDAS® CHIKUNGUNYA panel provides an easy-to-use, flexible and cost-effective solution for automated chikungunya diagnosis.
References
VIDAS® Anti-CHIKUNGUNYA IgM&IgG developed with the contribution of the United States National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC).
VIDAS® Anti-CHIKUNGUNYA IgM | VIDAS® Anti-CHIKUNGUNYA IgG | |
Reference | 423229-30 / 423229 | 423230-30 / 423230 |
Tests / kit | 30 / 60 | 30 / 60 |
Sample type | 30 | 30 |
Calibration frequency | Only 56 days | Only 56 days |
Shelf life | 12 months | 12 months |
VIDAS® Anti-CHIKUNGUNYA IgM&IgG developed with the contribution of the United States National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC).
VIDAS® Anti-CHIKUNGUNYA IgM&IgG developed with the contribution of the United States National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC).